Publication: The influence of VKORC1 polymorphisms on warfarin doses in thai patients with deep vein thrombosis
Issued Date
2015-01-01
Resource Type
ISSN
01252208
01252208
01252208
Other identifier(s)
2-s2.0-84933518407
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Journal of the Medical Association of Thailand. Vol.98, No.6 (2015), 549-554
Suggested Citation
Nuttawut Sermsathanasawadi, Chukij Sritongsathian, Nunthapol Pongrattanaman, Banjerd Praditsuktavorn, Kiattisak Hongku, Chumpol Wongwanit, Chanean Ruangsetakit, Khamin Chinsakchai, Pramook Mutirangura, Naravat Poungvarin The influence of VKORC1 polymorphisms on warfarin doses in thai patients with deep vein thrombosis. Journal of the Medical Association of Thailand. Vol.98, No.6 (2015), 549-554. Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/36540
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
The influence of VKORC1 polymorphisms on warfarin doses in thai patients with deep vein thrombosis
Other Contributor(s)
Abstract
© 2015, Medical Association of Thailand. All rights reserved. Background: Polymorphisms in cytochrome P450 2C9 and vitamin K epoxide reductase complex, subunit 1 genes (CYP2C9 and VKORC1, respectively) were previously shown to affect the warfarin dose required in anticoagulant therapy of deep vein thrombosis (DVT). However, little is known about the role of these genetic variants in the Thai population. Objective: To identify the effect of CYP2C9 and VKORC1 genetic variants on warfarin dosage in the Thai population with DVT. Material and Method: Genotyping of CYP2C9 (*2 and *3) and VKORC1 promoter (-1639G>A) variants were carried out in 97 Thai DVT patients receiving constant warfarin therapy and with a stable international normalized ratio using real-time PCR assays. Results: VKORC1 AA, GA, and GG genotype frequencies were found to be 49.5%, 46.4%, and 4.1%, respectively, while those of CYP2C9 genotypes were 88.7% for *1/*1 and 11.3% for *1/*3. The CYP2C9*2 variant was not present in the patients studied. The mean daily warfarin dose required to maintain a therapeutic INR differed significantly according to VKORC1 genotype, with 3.6 mg/day required for AA, 4.7 mg/day for GA, and 7.4 mg/day for GG (p-value <0.001). The CYP2C9 genotype did not significantly affect the warfarin dosage requirement (p-value = 0.29). Conclusion: These findings underline the impact of VKORC1 genotypes on the wide variation in warfarin maintenance dosing in Thai patients with DVT.